Author(s): Amirghofran Z, Daneshbod Y, Gholijani N, Esmaeilbeig M
Abstract Share this page
Abstract BACKGROUND: The possible prognostic significance of the expression of a variety of markers has been investigated in acute lymphoblastic leukemia (ALL). METHODS: In the present study we investigated the prognostic significance of CD13 and CD33 myeloid antigens (MY) aberrantly expressed on the blasts of ALL patients and Bcl-2 anti- apoptotic molecule expression in childhood ALL. RESULTS: Aberrant expression of MY occurred in 8.8\% of cases. Variant levels of Bcl-2 were expressed in patients (44.2±25.5\%), with more than 20\% positivity for Bcl-2 in 64.7\% of patients. Bcl-2+ patients survived 959±242 days compared to 1059+230 days for Bcl-2- patients (P=0.2). Corresponding data for complete remission duration was 682±170 and 716±173 days (P=0.3), respectively, indicating no significant association between survival and complete remission duration of patients with expression of the Bcl-2 molecule. Analysis of clinical response according to MY expression, however, showed significant association with survival and complete remission duration. MY+ patients had shorter complete remission duration (383±58 days) and survival (473±68 days) than MY- patients (complete remission duration, 724±144 days; survival, 1045±186 days; P<0.001). Expression of Bcl-2 along with MY was not associated with a significant decrease in survival or complete remission duration. CONCLUSION: Results of this study indicated that expression of MY was a poor prognostic factor in childhood ALL. Bcl-2 expression in MY+ patients could not influence the response to therapy.
This article was published in Arch Iran Med
and referenced in Journal of Cancer Science & Therapy